5/10/2013 9:26:30 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
NEW YORK, May 9, 2013 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, today reported its financial results and business update for the first quarter ended March 31, 2013. Synergy is developing plecanatide for the treatment of chronic idiopathic constipation (CIC) and constipation-predominant irritable bowel syndrome (IBS-C).
Help employers find you! Check out all the jobs and post your resume.
comments powered by